


Mitochondria pathology

Genetic pathologies caused by mutations of mitochondrial proteins




1962. The first discovered pathology: Luft Disease loss of uncoupling of mitochondrial respiration and ATP synthesis in skeletal muscle tissue

1988. Identification of the first mutations of mtDNA in a rare optic myopathy

Today. OX-PHOS alterations are frequent causes of degenerative disorders. A frequency of about 1/10.000 births


MITOCHONDRIA: structure - function

- Most of the mitochondrial proteins are coded by nuclear DNA (nDNA).
- Transduced in cytoplasm and through the “leader peptide” transported in mitochondria



Mitochondria are endosymbiotic prokaryotes with their own DNA (mtDNA)

MITOCHONDRION: oxidative phosphorylation (OXPHOS)



COMPLEX I: NADH DEHYDROGENASE
 30 polypeptides
7 mitochondrial polypeptides

COMPLEX II: SUCCINATE DEHYDROGENASE
 4 nuclear polypeptides

COMPLEX III: CYTOCHROME C REDUCTASE
 10 polypeptides
1 mitochondrial polypeptide (cytochrome b)

COMPLEX IV: CYTOCHROME C OXIDASE
 13 polypeptides
3 mitochondrial polypeptides


COMPLEX V: ATP SYNTHASE
 12 polypeptides
2 mitochondrial polypeptides (ATPase 6 - ATPase 8)

mtDNA Features

Circular Double strand DNA of 16.569 bp

2/10 molecules of mtDNA/mitochondrion 10^3 10^4 molecules mtDNA/cell

- 37 genes: 24 RNA for protein synthesis
- 22 tRNA
- 2 rRNA (12S e 16S)
- 13 proteins,
- enzyme subunits of the respiratory chain regulation of the oxidative phosphorylation
- Polymerases coded by nDNA



mtDNA Features

Both mtDNA strands are transcribed to generate long **POLYCISTRONS** processed to release :

tRNA
rRNA
mRNA


Percentage of mutations 10 > NUCLEAR DNA:

- lack of HISTONES
- Lack of DNA repair systems
- Damage by free radicals

- Asynchronous and independent replication mtDNA /nDNA
- Random distribution in terms of numbers of mtDNA molecules in daughter cells
- No recombination between single mtDNA molecules
- New alleles --> spontaneous mutations
- **Exclusively MATERNAL inheritance**
(mainly transmitted through oocytes cytoplasm)
- Variability in clinical manifestations in affected relatives
- **HETEROPLASMY:** presence of mutated and normal mtDNA in the same cell
- Replicative segregation --> **HOMOPLASMY**
only one kind of mtDNA

Mitochondrial Genetics

- Maternal inheritance exclusively
- Prone to accumulate somatic mutations with age



Genetic mitochondrial pathology

ALTERATIONS --> wide range of molecular mitochondrial pathology

GENETIC CAUSES { nuclear DNA mutations (mendelian trait)
mtDNA mutations (maternal inheritance – sporadic f.)

mtDNA MUTATIONS

A) REARRANGEMENTS { Deletions
Duplications

Defective protein synthesis
OXPHOS defects

B) POINT MUTATIONS tRNA

Defective protein synthesis

C) POINT MUTATIONS of polypeptides of rRNA
OXPHOS

Spontaneous Mutations :
Germinal (maternal inheritance)
Somatic (sporadic diseases)

nDNA MUTATIONS


A) Missense / deletion MUTATIONS of OXPHOS complex genes

B) Missense / deletion MUTATIONS of other mt protein genes

C) DESTABILIZATION of mt DNA

Mitochondrial diseases with onset early in infancy/childhood

Severe psychomotor delay, generalized hypotonia, lactic acidosis, cardiorespiratory failure



LEIGH, Rearrangements of mtDNA: Kearns-Sayre, Pearson

LEIGH and NARP SYNDROME

(Neurogenic muscle weakness, Ataxia, Retinitis Pigmentosa)

Alteration of ATP synthase

Point mutations of mtDNA

Most frequent:

MTATP6*NARP - T8993---> Leu 156 ---> Arg


MTATP6*FBSN - 9176 ---> Leu 217 ---> Pro

block of protons translocation- channel complex V

Maternal Inheritance with constant **HETEROPLASMY**:
correlation between mutated mtDNA and morbidity

High levels >95%: severe Leigh S. infantile onset

Low levels <75% NARP delayed onset



Kearn-Sayre SYNDROME (KSS) and CPEO

(Chronic progressive external ophthalmoplegia)

Mainly sporadic pathologies

Chronic progressive ophthalmoplegia
Mitochondrial Myopathy (RRF)

Retinitis pigmentosa

Lactic Acidosis

Neurosensory loss of hearing

Ataxia

Epileptic attack

Dementia

Hypertrophic and dilatative cardiomyopathy
defects of conductance

CPEO
After age 20

Kearn-Sayre
Syndrome before
age 20



- 83 % of KSS and 47% CPEO ---> mtDNA rearrangements
- Prevalent deletions (with or without duplications) **repetitive sequences** are involved
- Blood cells characteristically have no mutations in CPEO.
- **Positive Segregation of mutated forms**
- Mostly are new cases of sporadic and spontaneous mutations occurring early in development (oocyte??)
- Constant **HETEROPLASMY** between normal mtDNA and mutated mtDNA

Kearn-Sayre Syndrome (KSS) and CPEO

Deletions: ranging from 9 to 50% of mtDNA is removed

Frequent Deletions *1,3 - 7,6 Kb mtDNA*
nt 7194 - nt 14595 = 7,4 Kb

↓
Deletion of tRNA genes and OXPHOS proteins

↓
Reduced proteins synthesis

↓
Reduction of OXPHOS

Few case reports of KSS/CPEO are mitochondrial **tRNA mutations**

Pearson Syndrome

Mainly sporadic

multisystemic disorder characterized by:

Bone marrow pancytopenia

Pancreatic fibrosis ---> diabetes

Spleen atrophy

Hepatic and renal failure

- Children are affected. It is often lethal
- Survivors progress to → KSS phenotype

Molecular causes: defective function of OXPHOS due to reduced **COMPLEX I activity**

Several Deletions: 2461 bp 10367 - 12828
flanked by GCC sequences

Deletion/duplication of mtDNA is **HOMOPLASMIC** in blood cells-----> pancytopenia


Defects of subunits. **ND3, ND4L, ND4, ND5 of complex I**

Defects of **tRNA** (Arg His Ser Leu)

Mitochondrial diseases with onset in late childhood or adult life

Myopathy, variable involvement of CNS.

Muscle weakness, wasting with exercise intolerance.



LOHN, MELAS, NARP, and CPEO


Optic Neuropathy of Leber (LHON)

Molecular basis and Pathophysiology

- **18 point mutations of mtDNA coding proteins of COMPLEX I (NADH dehydrogenase) (90% of affected)**
- **Low efficiency of oxydative phosphorylation (OXPHOS)**
- **ATP deficiency leading neurons of optic nerve to death**
- **More ROS**
 - **channel opening mtPTP ---> apoptosis**
 - **inhibited release of NO --> vasoconstriction and vasculopathy**
- **Found new “primary” mutations of mtDNA of **Complex IV subunit III: cytochrome C oxidase****
- **SECONDARY MUTATIONS:** associated to primary mutations: synergistic action

OPTIC NEUROPATHY of Leber (LHON)


Alterations of NADH dehydrogenase



Most frequent Mutations


- 1. MTND4*LHON - G11778A ---> Arg 340 ---> Hys (**subunit ND4**)
- **most frequent** variable penetrance and some normal phenotypes
- 2. MTND1*LHON - G3460A ---> Ala 52 --> Thr (**subunit ND1**)
- second in pathogenicity
- 3. MTND6*LHON - A14484C ---> Met 64 --> Val
- (highly conserved domain of **ND6**)
- more benign sometimes vision recovery
- 4. MTND6*LDYT- A14459G ---> Ala 72 --> Val (subunit **ND6**)
- most frequently heteroplasmic **more pathogenic, associated to dystonia**

A) “Ragged-Red-Fibers”



* Granular red areas


B)



Abnormal mitochondrial deposits

MERRF (Myoclonic Epilepsy and Ragged Red Fiber)


Molecular basis-MERRF SYNDROME



tRNA^{Lys} 8344A --> G in TΨ loop: highly conserved nucleotide
mut. 80-100% present
functionally recessive
affected interaction with ribosome
protein synthesis
function of complexes I and IV

tRNA^{Lys} 8356T --> C stem TΨ loop: - highly conserved nucleotide
mut. less frequent
functionally recessive
protein synthesis

Rearrangements of mtDNA



- Deletions / duplications Range from 2 - 8 Kb. Flanking repetitive sequences
- Affected ADULTS have:
 - - deleted mtDNA mainly in muscle and brain
 - - Development of progressive external opthalmoplegia (PEO)
 - - KEARNS-SAYRE SYNDROME (the most severe)
- Affected Children have:
 - - severe multisystemic disorders (anemia, exocrine pancreatic failure , diabetes mellitus, nephropathy, hepatopathy, eczema, other endocrine disorders)
- Diseases associated with deletions progress with age because the ratio mutated mtDNA / normal mtDNA increases.

MELAS


(Mitochondrial encephalomyopathy lactic acidosis stroke)

Molecular basis

Point mutations of tRNA of mtDNA: Heteroplasmic mutations

tRNA^{Leu(UUR)} 3243 A --> G loop of dihydrouridine:

- ↓ Alterations in tertiary structures
- ↓ tRNA stability
- ↓ ability to interact with aa LEU
- ↓ assembly ability tRNA with ribosome



REDUCED MITOCHONDRIAL PROTEIN SYNTHESIS

> 85% mtDNA ---> MELAS

5 - 35% mtDNA -> associated to diabetes mellitus type II maternally inherited and deafness

tRNA^{Leu(UUR)} 3271T --> C terminal nucleotide of anticodon:


tRNA^{Leu(UUR)} 3251A --> G loop di dihydrouridine

Other non characterized mutations of mtDNA

Mutations of nuclear DNA

Diagnosis of mtDNA disease

- Clinical testing
- Histochemical and biochemical assays
- Molecular genetic testing




H&E

Gomori trichrome

SDH

COX

COX-SDH



LOHN and MERRF

Source: D. L. Kasper, A. S. Fauci, S. L. Hauser, D. L. Longo, J. L. Jameson, J. Loscalzo: Harrison's Principles of Internal Medicine, 19th Edition
www.accessmedicine.com

Copyright © McGraw-Hill Education. All rights reserved.


For educational purposes only

Other disease associated to mitochondrial DNA abnormalities

mtDNA anomalies cause more severe forms with late onset and related to age. Neurodegenerative diseases, diabetes mellitus, cardiomyopathy, deafness, dementia, Alzheimer

CAUSE: genetic predisposition
decreased OXPHOS age correlated

mtDNA somatic mutations ---> postmitotic tissue with high energy requirement
ATP (muscle and brain)




Oxidative
Damage

In example: Deletion 4977 (5 Kb) accumulates in basal ganglia and in other cortical regions of brain after age 75.

Threshold hypothesis

OXPHOS Capacity vs. mtDNA Damage



For educational purposes only

Genetic mitochondrial pathology



Pathophysiology of mitochondrial genetics

DEFECTS in ENERGETIC METABOLISM



Free radicals production (ROS)



APOPTOSIS

Accumulation of postmitotic mutations:

DEGENERATIVE PATHOLOGIES

AGING- COMMON DISEASES



Clinical variability---> HETEROPLASMA - % mutated mtDNA and energy request by the target tissues

**Same Mutations---> DIFFERENT MITOCHONDRIAL SYNDROMES
(multifactorial elements)**

Therapeutic options in management of mtDNA disease

- **Exercise therapy** to improve physical capacity and quality of life
- **Substrates, carriers and antioxidant**
- **Gene Therapy:** manipulation of heteroplasmy levels to shift the balance of **mutant** to **wt** genomes.
- **Prevention of mtDNA disease transmission**
- Perspectives
- Cataloguing and understanding the mtDNA defects responsible for the development to uncover novel protein targets or molecular pathways that may be exploited for therapy development.

Diseases and symptoms in energy consuming tissues and organs dependent on mtDNA alterations

